Effect of APPswe on the osteogenic differentiation of MSCs induced by BMP2. (IMAGE)
Caption
(A, B) ALP staining and activity detection were performed after treating cells with APPswe or BMP2 for 5 days or 7 days. (C, D) ARS staining and semiquantitative analysis were used to detect calcium nodule formation after cells were treated with APPswe or BMP2 for 21 days. (E) The mRNA expression levels of genes related to osteogenic differentiation were measured by quantitative real-time PCR after cells were treated with APPswe or BMP2 for 48 h. (F) Western blot analysis was performed to detect the expression levels of osteogenic differentiation-related proteins after cells were treated with APPswe or BMP2 for 48 h. (G) The expression levels of the osteogenic differentiation proteins p-Smad1/5/8 and OCN in the different treatment groups were detected by cell immunofluorescence. MSCs were treated with APPswe for 24 h and then with BMP2 for 48 h to detect the expression of related proteins or mRNAs. n = 3; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. APPswe, Swedish mutant amyloid precursor protein; MSC, mesenchymal stem cell; ALP, alkaline phosphatase; BMP2, bone morphogenetic protein 2; OCN, osteocalcin.
Credit
Genes & Diseases
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND